Anagrelide

An update on its mechanisms of action and therapeutic potential

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Thrombocytosis is an increasingly recognized clinical problem due to the widespread availability of automated cell counters. While reactive thrombocytosis does not require any therapeutic intervention, clonal thrombocytosis may require therapy to prevent thrombohemorrhagic complications. The clinician has a number of therapeutic options available when confronted with a patient having clonal thrombocytosis. One of these agents is anagrelide (Agrylin®, Bristol-Myers Squibb). In this drug profile, a synopsis of the available data on this agent and its role in the control of thrombocytosis will be provided. The main side effects of the medication are discussed, as well as the potential future developments in the field.

Original languageEnglish (US)
Pages (from-to)533-541
Number of pages9
JournalExpert Review of Anticancer Therapy
Volume4
Issue number4
StatePublished - Aug 2004

Fingerprint

Thrombocytosis
Action Potentials
Therapeutics
anagrelide
Pharmaceutical Preparations

Keywords

  • Anagrelide
  • Essential thrombocythemia
  • Myeloproliferative disorders
  • Thrombocytosis

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Anagrelide : An update on its mechanisms of action and therapeutic potential. / Dingli, David M; Tefferi, Ayalew.

In: Expert Review of Anticancer Therapy, Vol. 4, No. 4, 08.2004, p. 533-541.

Research output: Contribution to journalArticle

@article{fcff57f8002345939eda48da67b3ce45,
title = "Anagrelide: An update on its mechanisms of action and therapeutic potential",
abstract = "Thrombocytosis is an increasingly recognized clinical problem due to the widespread availability of automated cell counters. While reactive thrombocytosis does not require any therapeutic intervention, clonal thrombocytosis may require therapy to prevent thrombohemorrhagic complications. The clinician has a number of therapeutic options available when confronted with a patient having clonal thrombocytosis. One of these agents is anagrelide (Agrylin{\circledR}, Bristol-Myers Squibb). In this drug profile, a synopsis of the available data on this agent and its role in the control of thrombocytosis will be provided. The main side effects of the medication are discussed, as well as the potential future developments in the field.",
keywords = "Anagrelide, Essential thrombocythemia, Myeloproliferative disorders, Thrombocytosis",
author = "Dingli, {David M} and Ayalew Tefferi",
year = "2004",
month = "8",
language = "English (US)",
volume = "4",
pages = "533--541",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Anagrelide

T2 - An update on its mechanisms of action and therapeutic potential

AU - Dingli, David M

AU - Tefferi, Ayalew

PY - 2004/8

Y1 - 2004/8

N2 - Thrombocytosis is an increasingly recognized clinical problem due to the widespread availability of automated cell counters. While reactive thrombocytosis does not require any therapeutic intervention, clonal thrombocytosis may require therapy to prevent thrombohemorrhagic complications. The clinician has a number of therapeutic options available when confronted with a patient having clonal thrombocytosis. One of these agents is anagrelide (Agrylin®, Bristol-Myers Squibb). In this drug profile, a synopsis of the available data on this agent and its role in the control of thrombocytosis will be provided. The main side effects of the medication are discussed, as well as the potential future developments in the field.

AB - Thrombocytosis is an increasingly recognized clinical problem due to the widespread availability of automated cell counters. While reactive thrombocytosis does not require any therapeutic intervention, clonal thrombocytosis may require therapy to prevent thrombohemorrhagic complications. The clinician has a number of therapeutic options available when confronted with a patient having clonal thrombocytosis. One of these agents is anagrelide (Agrylin®, Bristol-Myers Squibb). In this drug profile, a synopsis of the available data on this agent and its role in the control of thrombocytosis will be provided. The main side effects of the medication are discussed, as well as the potential future developments in the field.

KW - Anagrelide

KW - Essential thrombocythemia

KW - Myeloproliferative disorders

KW - Thrombocytosis

UR - http://www.scopus.com/inward/record.url?scp=4444268727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444268727&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 533

EP - 541

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 4

ER -